Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00073554 · ClinicalTrials.gov registry record · Phase 2
Alfimeprase for Thrombolysis in Acute Peripheral Arterial Occlusion
A Phase 2 study of Thrombosis and Peripheral Vascular Diseases, sponsored by ARCA Biopharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT00073554: Completed Phase 2 study of Thrombosis and Peripheral Vascular Diseases, sponsored by ARCA Biopharma.
NCT00073554 is a Phase 2 study of Thrombosis and Peripheral Vascular Diseases that has completed, run by ARCA Biopharma. The registered enrollment target is 100 participants, below the 467-participant average among 28 other Thrombosis trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00073554, a Phase 2 study of Thrombosis and Peripheral Vascular Diseases, has completed, sponsored by ARCA Biopharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial is for patients with acute occlusion of one of the arteries supplying blood to the leg. The trial is designed to determine the safety and activity of a novel clot dissolving (thrombolytic) drug (alfimeprase).
Conditions Studied
Interventions
- DRUG Alfimeprase
Study Locations (1)
Ohio
- Cleveland Clinic Foundation - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2003-06 |
| Phase | Phase 2 |
What the finished NCT00073554 record still lists
NCT00073554 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 467-participant average among 28 other Thrombosis trials with a reported enrollment target (79% lower).
The record links to 3 conditions, with Thrombosis appearing as the primary indexed condition, and to 1 intervention - of which Alfimeprase is the first listed.
NCT00073554 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT00073554 about?
NCT00073554 is a clinical study titled "Alfimeprase for Thrombolysis in Acute Peripheral Arterial Occlusion". This trial is for patients with acute occlusion of one of the arteries supplying blood to the leg. The trial is designed to determine the safety and activity of a novel clot dissolving (thrombolytic) drug (alfimeprase).
What is the current status of trial NCT00073554?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2003-06.
What conditions does trial NCT00073554 study?
This clinical trial studies the following conditions: Thrombosis, Peripheral Vascular Diseases, Arterial Occlusive Diseases.
What interventions are being tested in trial NCT00073554?
The interventions under investigation include: Alfimeprase (DRUG).
Who is sponsoring clinical trial NCT00073554?
This trial is sponsored by ARCA Biopharma, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00073554 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thrombosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00073554's enrollment target sits among peer trials
100 13th of 28 higher than 16 of 28 other Thrombosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thrombosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"
COMPLETED · Phase 2
-
A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery
COMPLETED · Phase 2
-
Study Of Angiomax In Infants Under Six Months With Thrombosis
COMPLETED · Phase 2
-
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
RECRUITING
-
Positron Emission Tomography (PET) Imaging of Thrombosis
RECRUITING · Phase 1
-
Pharmacogenomics of Warfarin in Hispanics and Latinos
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia